Predicting and preventing stroke after transient ischemic attack

Expert Review of Neurotherapeutics

Volumn 9, Issue 8, 2009, Pages 1159-1170

  De Lau, Lonneke M L ^a   Den Hertog, Heleen M ^a   Van Den Herik, Evita G ^a   Koudstaal, Peter J ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Lifestyle; Prognosis; Risk factors; Risk prediction; Secondary prevention; Stroke; Transient ischemic attack

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; BIOLOGICAL MARKER; CLOPIDOGREL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PIOGLITAZONE; SIMVASTATIN;

CAROTID ARTERY SURGERY; CLINICAL TRIAL; COMPUTED TOMOGRAPHIC ANGIOGRAPHY; DECISION MAKING; DIABETES MELLITUS; DIFFUSION WEIGHTED IMAGING; DISEASE COURSE; DOPPLER FLOWMETRY; DRUG EFFICACY; DRUG RESPONSE; ELECTROMYOGRAPHY; EMBOLISM; FOLLOW UP; GASTROINTESTINAL HEMORRHAGE; GENETIC VARIABILITY; GENOME; HEALTH CARE PLANNING; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HIGH RISK PATIENT; HUMAN; IMPAIRED GLUCOSE TOLERANCE; ISCHEMIA; LIFESTYLE; MORBIDITY; NUCLEAR MAGNETIC RESONANCE IMAGING; PRACTICE GUIDELINE; PREDICTION; PROGNOSIS; REVIEW; RISK ASSESSMENT; SCORING SYSTEM; SECONDARY PREVENTION; SINGLE NUCLEOTIDE POLYMORPHISM; STROKE; TRANSIENT ISCHEMIC ATTACK; TRANSTHORACIC ECHOCARDIOGRAPHY; TREATMENT OUTCOME;

HUMANS; ISCHEMIC ATTACK, TRANSIENT; PLATELET AGGREGATION INHIBITORS; PREDICTIVE VALUE OF TESTS; RISK FACTORS; STROKE;

EID: 70349462777     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/ern.09.71     Document Type: Review

References (111)

1. A classification and outline of cerebrovascular diseases II. Stroke 6(5), 564-616 (1975).
2. Koudstaal PJ, Gerritsma JG, van Gijn J. Clinical disagreement on the diagnosis of transient ischemic attack: is the patient or the doctor to blame? Stroke 20(2), 300-301 (1989).
3. Albers GW, Caplan LR, Easton JD et al. Transient ischemic attack: proposal for a new definition. N. Engl. J. Med. 347(21), 1713-1716 (2002).
4. Engelter ST, Provenzale JM, Petrella JR, Alberts MJ. Diffusion MR imaging and transient ischemic attacks. Stroke 30(12), 2762-2763 (1999).
5. Crisostomo RA, Garcia MM, Tong DC. Detection of diffusion-weighted MRI abnormalities in patients with transient ischemic attack: correlation with clinical characteristics. Stroke 34(4), 932-937 (2003).
6. Redgrave JN, Coutts SB, Schulz UG, Briley D, Rothwell PM. Systematic review of associations between the presence of acute ischemic lesions on diffusion-weighted imaging and clinical predictors of early stroke risk after transient ischemic attack. Stroke 38(5), 1482-1488 (2007). (Pubitemid 46684149)
7. Kidwell CS, Alger JR, Di Salle F et al. Diffusion MRI in patients with transient ischemic attacks. Stroke 30(6), 1174-1180 (1999). (Pubitemid 29259169)
8. Levy DE. How transient are transient ischemic attacks? Neurology 38(5), 674-677 (1988).
9. Marler JR, Tilley BC, Lu M et al. Early stroke treatment associated with better outcome: the NINDS rt-PA stroke study. Neurology 55(11), 1649-1655 (2000).
10. Hollander M, Koudstaal PJ, Bots ML et al. Incidence, risk, and case fatality of first ever stroke in the elderly population. the Rotterdam Study. J. Neurol. Neurosurg. Psychiatr. 74(3), 317-321 (2003). (Pubitemid 36259354)
11. Bos MJ, van Rijn MJ, Witteman JC et al. Incidence and prognosis of transient neurological attacks. JAMA 298(24), 2877-2885 (2007). Large population-based study among 6062 participants aged 55 years and older evaluating the association between transient neurological attacks (focal, nonfocal and mixed) and the risk of subsequent stroke, ischemic heart disease and dementia.
12. van Swieten JC, Kappelle LJ, Algra A et al. Hypodensity of the cerebral white matter in patients with transient ischemic attack or minor stroke: influence on the rate of subsequent stroke. Dutch TIA trial study group. Ann. Neurol. 32(2), 177-183 (1992).
13. Sempere AP, Duarte J, Cabezas C, Claveria LE. Incidence of transient ischemic attacks and minor ischemic strokes in Segovia, Spain. Stroke 27(4), 667-671 (1996). (Pubitemid 26114429)
14. Ricci S, Celani MG, Guercini G et al. First-year results of a community-based study of stroke incidence in Umbria, Italy. Stroke 20(7), 853-857 (1989). (Pubitemid 19188238)
15. Bejot Y, Rouaud O, Benatru I et al. Trends in the incidence of transient ischemic attacks, premorbid risk factors and the use of preventive treatments in the population of Dijon, France from 1985 to 2004. Cerebrovasc. Dis. 23(2-3), 126-131 (2007).
16. Feigin VL, Shishkin SV, Tzirkin GM et al. A population-based study of transient ischemic attack incidence in Novosibirsk, Russia, 1987-1988 and 1996-1997. Stroke 31(1), 9-13 (2000).
17. Rothwell PM, Coull AJ, Giles MF et al. Change in stroke incidence, mortality, case-fatality, severity, and risk factors in Oxfordshire, UK from 1981 to 2004 (Oxford Vascular Study). Lancet 363(9425), 1925-1933 (2004).
18. Brown RD Jr, Petty GW, O'Fallon WM, Wiebers DO, Whisnant JP. Incidence of transient ischemic attack in Rochester, Minnesota, 1985-1989. Stroke 29(10), 2109-2113 (1998).
19. Kleindorfer D, Panagos P, Pancioli A et al. Incidence and short-term prognosis of transient ischemic attack in a population-based study. Stroke 36(4), 720-723 (2005). (Pubitemid 40490612)
20. Giles MF, Rothwell PM. Substantial underestimation of the need for outpatient services for TIA and minor stroke. Age Ageing 36(6), 676-680 (2007).
21. Hankey GJ, Slattery JM, Warlow CP. The prognosis of hospital-referred transient ischaemic attacks. J. Neurol. Neurosurg. Psychiatr. 54(9), 793-802 (1991).
22. Farrell B, Godwin J, Richards S, Warlow C. The United Kingdom transient ischaemic attack (UK-TIA) aspirin trial: final results. J. Neurol. Neurosurg. Psychiatr. 54(12), 1044-1054 (1991).
23. The Dutch TIA trial: protective effects of low-dose aspirin and atenolol in patients with transient ischemic attacks or nondisabling stroke. the Dutch TIA Study Group. Stroke 19(4), 512-517 (1988).
24. Rothwell PM, Warlow CP. Timing of TIAs preceding stroke: time window for prevention is very short. Neurology 64(5), 817-820 (2005).
25. Johnston SC, Gress DR, Browner WS, Sidney S. Short-term prognosis after emergency department diagnosis of TIA. JAMA 284(22), 2901-2906 (2000). First study with prospective evaluation of the early risk of stroke after transient ischemic attacks (TIA), estimating a 3-month risk of stroke of 10.5%.
26. Daffertshofer M, Mielke O, Pullwitt A, Felsenstein M, Hennerici M. Transient ischemic attacks are more than "ministrokes". Stroke 35(11), 2453-2458 (2004).
27. Coull AJ, Lovett JK, Rothwell PM. Population based study of early risk of stroke after transient ischaemic attack or minor stroke: implications for public education and organisation of services. BMJ 328(7435), 326 (2004).
28. Lovett JK, Dennis MS, Sandercock PA et al. Very early risk of stroke after a first transient ischemic attack. Stroke 34(8), E138-E140 (2003).
29. Correia M, Silva MR, Magalhaes R, Guimaraes L, Silva MC. Transient ischemic attacks in rural and urban northern Portugal: incidence and short-term prognosis. Stroke 37(1), 50-55 (2006). (Pubitemid 43732047)
30. Giles MF, Rothwell PM. Risk of stroke early after transient ischaemic attack: a systematic review and meta-analysis. Lancet Neurol. 6(12), 1063-1072 (2007). Meta-analysis of 18 prospective studies evaluating the early risk of stroke of, in total, 10,126 TIA patients. Substantial heterogeneity amoung studies was found, illustrating the influence on measured stroke risk of factors such as delay between TIA and study entry, thoroughness of follow-up, setting in which the study was performed (general population, emergency department or specialist stroke service), and timing and intensity of initiated therapy.
31. Wu CM, McLaughlin K, Lorenzetti DL et al. Early risk of stroke after transient ischemic attack: a systematic review and meta-analysis. Arch. Intern. Med. 167(22), 2417-2422 (2007). (Pubitemid 350258447)
32. Rothwell PM, Giles MF, Flossmann E et al. A simple score (ABCD) to identify individuals at high early risk of stroke after transient ischaemic attack. Lancet 366(9479), 29-36 (2005). Development of a simple prediction score based on clinical characteristics to estimate the risk of stroke during the first 7 days following TIA. (Pubitemid 40956527)
33. Johnston SC, Rothwell PM, Nguyen-Huynh MN et al. Validation and refinement of scores to predict very early stroke risk after transient ischaemic attack. Lancet 369(9558), 283-292 (2007). Refinement of the ABCD score by adding a point for diabetes; the score was validated in four cohorts.
34. Douglas VC, Johnston CM, Elkins J et al. Head computed tomography findings predict short-term stroke risk after transient ischemic attack. Stroke 34(12), 2894-2898 (2003). (Pubitemid 37517764)
35. Sciolla R, Melis F. Rapid identification of high-risk transient ischemic attacks: prospective validation of the ABCD score. Stroke 39(2), 297-302 (2008). (Pubitemid 351619447)
36. Oppenheim C, Lamy C, Touze E et al. Do transient ischemic attacks with diffusion-weighted imaging abnormalities correspond to brain infarctions? AJNR Am. J. Neuroradiol. 27(8), 1782-1787 (2006). (Pubitemid 44413572)
37. Purroy F, Montaner J, Rovira A et al. Higher risk of further vascular events among transient ischemic attack patients with diffusion-weighted imaging acute ischemic lesions. Stroke 35(10), 2313-2319 (2004). (Pubitemid 39311255)
38. Coutts SB, Simon JE, Eliasziw M et al. Triaging transient ischemic attack and minor stroke patients using acute magnetic resonance imaging. Ann. Neurol. 57(6), 848-854 (2005). (Pubitemid 40798623)
39. Sylaja PN, Coutts SB, Subramaniam S et al. Acute ischemic lesions of varying ages predict risk of ischemic events in stroke/ TIA patients. Neurology 68(6), 415-419 (2007). (Pubitemid 46208743)
40. Wen HM, Lam WW, Rainer T et al. Multiple acute cerebral infarcts on diffusion-weighted imaging and risk of recurrent stroke. Neurology 63(7), 1317-1319 (2004). (Pubitemid 39350043)
41. Valton L, Larrue V, le Traon AP, Massabuau P, Geraud G. Microembolic signals and risk of early recurrence in patients with stroke or transient ischemic attack. Stroke 29(10), 2125-2128 (1998). (Pubitemid 28443529)
42. Molloy J, Markus HS. Asymptomatic embolization predicts stroke and TIA risk in patients with carotid artery stenosis. Stroke 30(7), 1440-1443 (1999). (Pubitemid 29296074)
43. Lovett JK, Coull AJ, Rothwell PM. Early risk of recurrence by subtype of ischemic stroke in population-based incidence studies. Neurology 62(4), 569-573 (2004).
44. Ois A, Gomis M, Rodriguez-Campello A et al. Factors associated with a high risk of recurrence in patients with transient ischemic attack or minor stroke. Stroke 39(6), 1717-1721 (2008).
45. Jensen MB, Chacon MR, Sattin JA, Aleu A, Lyden PD. The promise and potential pitfalls of serum biomarkers for ischemic stroke and transient ischemic attack. Neurologist 14(4), 243-246 (2008).
46. Di Angelantonio E, De Castro S, Toni D et al. Determinants of plasma levels of brain natriuretic peptide after acute ischemic stroke or TIA. J. Neurol. Sci. 260(1-2), 139-142 (2007). (Pubitemid 47212217)
47. Dambinova SA, Khounteev GA, Skoromets AA. Multiple panel of biomarkers for TIA/stroke evaluation. Stroke 33(5), 1181-1182 (2002).
48. Jefferson AL, Massaro JM, Wolf PA et al. Inflammatory biomarkers are associated with total brain volume: the Framingham Heart Study. Neurology 68(13), 1032-1038 (2007).
49. Bos MJ, Schipper CM, Koudstaal PJ et al. High serum C-reactive protein level is not an independent predictor for stroke: the Rotterdam Study. Circulation 114(15), 1591-1598 (2006).
50. Flex A, Gaetani E, Papaleo P et al. Proinflammatory genetic profiles in subjects with history of ischemic stroke. Stroke 35(10), 2270-2275 (2004). (Pubitemid 39311248)
51. Ikram MA, Seshadri S, Bis JC et al. Genomewide association studies of stroke. N. Engl. J. Med. 360(17), 1718-1728 (2009).
52. Albers GW. A review of published TIA treatment recommendations. Neurology 62(8 Suppl. 6), S26-S28 (2004).
53. Guidelines for management of ischaemic stroke and transient ischaemic attack 2008. Cerebrovasc. Dis. 25(5), 457-507 (2008).
54. Rothwell PM, Giles MF, Chandratheva A et al. Effect of urgent treatment of transient ischaemic attack and minor stroke on early recurrent stroke (EXPRESS study): a prospective population-based sequential comparison. Lancet 370(9596), 1432-1442 (2007). Observational study evaluating the effect of urgent evaluation and treatment after TIA. The regimen in the second phase of the study (direct referral of patients without appointment, with treatment being initiated immediately after confirmation of the diagnosis of TIA or minor stroke) led to a reduction of the 3-month stroke risk of 80% compared with the first phase (referral to appointment-based clinic that offered treatment recommendations to the referring physician. (Pubitemid 47576154)
55. Lavallee PC, Meseguer E, Abboud H et al. A transient ischaemic attack clinic with round-the-clock access (SOS-TIA): feasibility and effects. Lancet Neurol. 6(11), 953-960 (2007). Another observational study on urgent evaluation and treatment after TIA, in which a round the clock TIA service was found to significantly reduce the risk of subsequent stroke. (Pubitemid 47570023)
56. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 324(7329), 71-86 (2002).
57. Algra A, van Gijn J. Aspirin at any dose above 30 mg offers only modest protection after cerebral ischaemia. J. Neurol. Neurosurg. Psychiatr. 60(2), 197-199 (1996). (Pubitemid 26044196)
58. A comparison of two doses of aspirin (30 mg vs. 283 mg a day) in patients after a transient ischemic attack or minor ischemic stroke:the Dutch TIA Trial Study Group. N. Engl. J. Med. 325(18), 1261-1266 (1991).
59. Campbell CL, Smyth S, Montalescot G, Steinhubl SR. Aspirin dose for the prevention of cardiovascular disease: a systematic review. JAMA 297(18), 2018-2024 (2007). (Pubitemid 46740354)
60. Bhatt DL, Fox KA, Hacke W et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N. Engl. J. Med. 354(16), 1706-1717 (2006).
61. Diener HC, Bogousslavsky J, Brass LM et al. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. Lancet 364(9431), 331-337 (2004). (Pubitemid 39458141)
62. Halkes PH, van Gijn J, Kappelle LJ, Koudstaal PJ, Algra A. Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial. Lancet 367(9523), 1665-1673 (2006). Randomized controlled trial comparing dipyridamole 200 mg twice daily plus aspirin (30-325 mg daily) with aspirin alone in 2703 patients who suffered a TIA or minor stroke of presumed arterial origin. Addition of the European/Australasian Stroke Prevention in Reversible Ischaemia Trial (ESPRIT) data to a meta-analysis of previous trials resulted in an overall risk ratio for the composite vascular death, stroke or myocardial infarction of 0.82 (95% CI: 0.74-0.91).
63. Armstrong PW, Fu Y, Chang WC et al. Acute coronary syndromes in the GUSTO-IIb trial: prognostic insights and impact of recurrent ischemia. the GUSTO-IIb investigators. Circulation 98(18), 1860-1868 (1998).
64. Sacco RL, Diener HC, Yusuf S et al. Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke. N. Engl. J. Med. 359(12), 1238-1251 (2008).
65. Cheng Y, Austin SC, Rocca B et al. Role of prostacyclin in the cardiovascular response to thromboxane A2. Science 296(5567), 539-541 (2002). (Pubitemid 34408674)
66. Bousser MG, Amarenco P, Chamorro A et al. Rationale and design of a randomized, double-blind, parallel-group study of terutroban 30 mg/day versus aspirin 100 mg/day in stroke patients: the prevention of cerebrovascular and cardiovascular events of ischemic origin with terutroban in patients with a history of ischemic stroke or transient ischemic attack (PERFORM) study. Cerebrovasc. Dis. 27(5), 509-518 (2009).
67. Gorog DA, Sweeny JM, Fuster V. Antiplatelet drug 'resistance'. part 2: laboratory resistance to antiplatelet drugs-fact or artifact? Nat. Rev. Cardiol. 6(5), 365-373 (2009).
68. Sweeny JM, Gorog DA, Fuster V. Antiplatelet drug 'resistance'. part 1: mechanisms and clinical measurements. Nat. Rev. Cardiol. 6(4), 273-282 (2009).
69. Anderson JL, Adams CD, Antman EM et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non ST-elevation myocardial infarction: a report of the American college of cardiology/american heart association task force on practice guidelines (writing committee to revise the 2002 guidelines for the management of patients with unstable angina/non ST-elevation myocardial infarction): developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons: endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. Circulation 116(7), E148-E304 (2007).
70. Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. EAFT (European Atrial Fibrillation Trial) Study Group. Lancet 342(8882), 1255-1262 (1993).
71. Optimal oral anticoagulant therapy in patients with nonrheumatic atrial fibrillation and recent cerebral ischemia: The European Atrial Fibrillation Trial Study Group. N. Engl. J. Med. 333(1), 5-10 (1995).
72. Hart RG, Pearce LA, Koudstaal PJ. Transient ischemic attacks in patients with atrial fibrillation: implications for secondary prevention: the European Atrial Fibrillation Trial and Stroke Prevention in Atrial Fibrillation III trial. Stroke 35(4), 948-951 (2004).
73. van Walraven C, Hart RG, Connolly S et al. Effect of age on stroke prevention therapy in patients with atrial fibrillation: the atrial fibrillation investigators. Stroke 40(4), 1410-1416 (2009).
74. A randomized trial of anticoagulants versus aspirin after cerebral ischemia of presumed arterial origin. The Stroke Prevention in Reversible Ischemia Trial (SPIRIT) Study Group. Ann. Neurol. 42(6), 857-865 (1997).
75. Saxena R, Lewis S, Berge E, Sandercock PA, Koudstaal PJ. Risk of early death and recurrent stroke and effect of heparin in 3169 patients with acute ischemic stroke and atrial fibrillation in the International Stroke Trial. Stroke 32(10), 2333-2337 (2001). (Pubitemid 32954805)
76. Lippi G, Franchini M, Favaloro EJ. Pharmacogenetics of vitamin K antagonists: useful or hype? Clin. Chem. Lab. Med. 47(5), 503-515 (2009).
77. Yusuf S, Sleight P, Pogue J et al. Effects of an angiotensin-converting- enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N. Engl. J. Med. 342(3), 145-153 (2000).
78. Bosch J, Yusuf S, Pogue J et al. Use of ramipril in preventing stroke: double blind randomised trial. BMJ 324(7339), 699-702 (2002). (Pubitemid 34259143)
79. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet 358(9287), 1033-1041 (2001).
80. Rashid P, Leonardi-Bee J, Bath P. Blood pressure reduction and secondary prevention of stroke and other vascular events: a systematic review. Stroke 34(11), 2741-2748 (2003). (Pubitemid 37392777)
81. Amarenco P, Bogousslavsky J, Callahan A 3rd et al. High-dose atorvastatin after stroke or transient ischemic attack. N. Engl. J. Med. 355(6), 549-559 (2006). Placebo-controlled trial among 4731 patients with a TIA or minor ischemic stroke of presumed arterial origin with a normal to high normal low-density lipoprotein cholesterol, showing a statistically significant relative risk reduction of 16% for recurrent stroke and a 35% reduction of major coronary events by atorvastatin 80 mg.
82. Amarenco P, Labreuche J, Lavallee P, Touboul PJ. Statins in stroke prevention and carotid atherosclerosis: systematic review and up-to-date meta-analysis. Stroke 35(12), 2902-2909 (2004). (Pubitemid 39565192)
83. Baigent C, Keech A, Kearney PM et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 366(9493), 1267-1278 (2005).
84. Fuentes B, Martinez-Sanchez P, Diez-Tejedor E. Lipid-lowering drugs in ischemic stroke prevention and their influence on acute stroke outcome. Cerebrovasc. Dis. 27(Suppl. 1), 126-133 (2009).
85. Barnett HJ, Taylor DW, Eliasziw M et al. Benefit of carotid endarterectomy in patients with symptomatic moderate or severe stenosis: North American Symptomatic Carotid Endarterectomy Trial collaborators. N. Engl. J. Med. 339(20), 1415-1425 (1998).
86. Randomised trial of endarterectomy for recently symptomatic carotid stenosis: final results of the MRC European Carotid Surgery Trial (ECST). Lancet 351(9113), 1379-1387 (1998).
87. Rothwell PM, Eliasziw M, Gutnikov SA et al. Analysis of pooled data from the randomised controlled trials of endarterectomy for symptomatic carotid stenosis. Lancet 361(9352), 107-116 (2003). (Pubitemid 36092014)
88. Rothwell PM, Eliasziw M, Gutnikov SA, Warlow CP, Barnett HJ. Endarterectomy for symptomatic carotid stenosis in relation to clinical subgroups and timing of surgery. Lancet 363(9413), 915-924 (2004). (Pubitemid 38388324)
89. Fisher M, Paganini-Hill A, Martin A et al. Carotid plaque pathology: thrombosis, ulceration, and stroke pathogenesis. Stroke 36(2), 253-257 (2005). (Pubitemid 40170802)
90. Rothwell PM, Gibson R, Warlow CP. Interrelation between plaque surface morphology and degree of stenosis on carotid angiograms and the risk of ischemic stroke in patients with symptomatic carotid stenosis.: on behalf of the European Carotid Surgery Trialists' Collaborative Group. Stroke 31(3), 615-621 (2000).
91. Eliasziw M, Streifler JY, Fox AJ et al. Significance of plaque ulceration in symptomatic patients with high-grade carotid stenosis. North American Symptomatic Carotid Endarterectomy Trial. Stroke 25(2), 304-308 (1994).
92. Endovascular versus surgical treatment in patients with carotid stenosis in the carotid and vertebral artery transluminal angioplasty study (CAVATAS): a randomised trial. Lancet 357(9270), 1729-1737 (2001).
93. Ringleb PA, Allenberg J, Bruckmann H et al. 30 day results from the SPACE trial of stent-protected angioplasty versus carotid endarterectomy in symptomatic patients: a randomised non-inferiority trial. Lancet 368(9543), 1239-1247 (2006).
94. Featherstone RL, Brown MM, Coward LJ. International carotid stenting study: protocol for a randomised clinical trial comparing carotid stenting with endarterectomy in symptomatic carotid artery stenosis. Cerebrovasc. Dis. 18(1), 69-74 (2004).
95. Hobson RW 2nd. CREST (Carotid Revascularization Endarterectomy versus Stent Trial): background, design, and current status. Semin. Vasc. Surg. 13(2), 139-143 (2000).
96. Thaler DE, Saver JL. Cryptogenic stroke and patent foramen ovale. Curr. Opin. Cardiol. 23(6), 537-544 (2008).
97. Stokes J 3rd, Kannel WB, Wolf PA, Cupples LA, D'Agostino RB. The relative importance of selected risk factors for various manifestations of cardiovascular disease among men and women from 35 to 64 years old: 30 years of follow-up in the Framingham Study. Circulation 75(6 Pt 2), V65-V73 (1987).
98. Wilcox R, Bousser MG, Betteridge DJ et al. Effects of pioglitazone in patients with type 2 diabetes with or without previous stroke: results from PROactive (PROspective pioglitAzone clinical trial in macrovascular events 04). Stroke 38(3), 865-873 (2007). (Pubitemid 46568445)
99. Urabe T, Watada H, Okuma Y et al. Prevalence of abnormal glucose metabolism and insulin resistance among subtypes of ischemic stroke in Japanese patients. Stroke 40(4), 1289-1295 (2009).
100. Gray CS, Scott JF, French JM, Alberti KG, O'Connell JE. Prevalence and prediction of unrecognised diabetes mellitus and impaired glucose tolerance following acute stroke. Age Ageing 33(1), 71-77 (2004).
101. Ivey FM, Ryan AS, Hafer-Macko CE et al. High prevalence of abnormal glucose metabolism and poor sensitivity of fasting plasma glucose in the chronic phase of stroke. Cerebrovasc. Dis. 22(5-6), 368-371 (2006).
102. Vermeer SE, Hollander M, van Dijk EJ et al. Silent brain infarcts and white matter lesions increase stroke risk in the general population: the Rotterdam Scan Study. Stroke 34(5), 1126-1129 (2003). (Pubitemid 36547501)
103. Kernan WN, Viscoli CM, Brass LM et al. The stroke prognosis instrument II (SPI-II): a clinical prediction instrument for patients with transient ischemia and nondisabling ischemic stroke. Stroke 31(2), 456-462 (2000).
104. Lee IM, Hennekens CH, Berger K, Buring JE, Manson JE. Exercise and risk of stroke in male physicians. Stroke 30(1), 1-6 (1999). (Pubitemid 29029432)
105. Robbins AS, Manson JE, Lee IM, Satterfield S, Hennekens CH. Cigarette smoking and stroke in a cohort of U.S. male physicians. Ann. Intern. Med. 120(6), 458-462 (1994). (Pubitemid 24075222)
106. Chiuve SE, Rexrode KM, Spiegelman D et al. Primary prevention of stroke by healthy lifestyle. Circulation 118(9), 947-954 (2008).
107. Giles MF. Risk of stroke and lifestyle. BMJ 338, B14 (2009).
108. Myint PK, Luben RN, Wareham NJ, Bingham SA, Khaw KT. Combined effect of health behaviours and risk of first ever stroke in 20,040 men and women over 11 years' follow-up in Norfolk cohort of European Prospective Investigation of Cancer (EPIC Norfolk): prospective population study. BMJ 338, B349 (2009). Observational epidemiological study evaluating the relationship between lifestyle behaviors and incident stroke in a cohort of 20,040 men and women aged 40-79 years. A higher score on four modifiable health behaviors indicating more protective behavior, was associated with a significantly lower risk of stroke.
109. Lindstrom J, Ilanne-Parikka P, Peltonen M et al. Sustained reduction in the incidence of Type 2 diabetes by lifestyle intervention: follow-up of the Finnish diabetes prevention study. Lancet 368(9548), 1673-1679 (2006). (Pubitemid 46048554)
110. Maasland L, van Oostenbrugge R, Franke C et al. Patients enrolled in large randomized clinical trials of antiplatelet treatment for prevention after TIA or ischemic stroke are not representative of patients in clinical practice: the Netherlands stroke survey. Stroke DOI: STROKEAHA.109.551812v1 (2009) (Epub ahead of print).
111. Rothwell PM. External validity of randomised controlled trials: "to whom do the results of this trial apply?" Lancet 365(9453), 82-93 (2005).